Beamr Imaging (BMR) Prices 1.71M Share Offering at $7/sh

Beamr Imaging Ltd. (Nasdaq: BMR) (“Beamr” or the “Company”), a leader in video optimization technology, today announced the pricing of an underwritten public offering of 1,714,200 ordinary shares. Each ordinary share is being sold at a public offering price of $7.00 per share for gross proceeds of approximately $12 million, before deducting underwriting discounts and offering expenses. All of the ordinary shares are being offered by the Company. In addition, Beamr has granted the underwriters a 45-day option to purchase up to an additional 257,100 ordinary shares to cover over-allotments at the public offering price, less the underwriting discount.

The Company intends to use the net proceeds for research and development efforts, sales and marketing activities, cloud operating costs, as well as general and administrative corporate purposes, including working capital and capital expenditures.

The offering is expected to close on February 15, 2024, subject to satisfaction of customary closing conditions.

ThinkEquity is acting as sole book-running manager for the offering.

A registration statement on Form F-1 (File No. 333-272257) relating to the shares was filed with the Securities and Exchange Commission (“SEC”) and became effective on February 12, 2024. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Sky Century Investment responds to OTC Markets stock promotion inquiry
• RenovoRx regains Nasdaq minimum bid price compliance
• Werewolf Therapeutics to merge with Ambros in $150M private placement